Pfizer informs about change in senior management personnel

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Pfizer has informed about the below changes in the Senior Management Personnel of the Company: (i) Nilesh Pendse is appointed as Category Lead – Vaccines of the Company with effect from February 1, 2026. Pendse shall accordingly be a Senior Management Personnel of the Company effective the said date. (ii) Manikantan Seshadrinathan – Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective February 1, 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective January 31, 2026. (iii) Prashant Mahalingam, Category Lead – Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead – Internal Medicine & Hospitals, effective February 1, 2026. The profile and other details of Mahalingam were already informed to the Stock Exchanges when he was appointed as Category Lead – Internal Medicine, vide its letter dated November 5, 2024. Additional details required to be disclosed pursuant to the SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of appointment referred to (i) above are enclosed as Annexure A.

The above information is a part of company’s filings submitted to BSE.